BOAN BIOTECH (06955) issued a profit warning, expecting a net loss attributable to shareholders of approximately 79 million to 89 million yuan for the interim period, a change from profit to loss compared to the same period last year.

BOAN BIOTECH (06955) announced that it expects the group to incur a net loss attributable to shareholders of approximately RMB 79 million to RMB 89 million for the six months ending June 30, 2026 (the reporting period), compared to a net profit attributable to shareholders of approximately RMB 21 million for the six months ending June 30, 2025. The board believes that the group's transition from profit to loss during the reporting period is mainly due to the increase in R&D expenses resulting from the acceleration of the group's innovation strategy, as multiple candidate drugs are advancing through clinical trials and critical preclinical studies, including BA1106 (anti-CD25 monoclonal antibody), BA1302 (targeting CD228 ADC), BA1203 (PD-1/IL-2 antibody prodrug), BA2201 (TL1A/IL-23p19 dual antibody), and BA1304 (EGFR/B7-H3 dual antibody ADC). As a result, the clinical trial expenses and R&D costs for these projects have significantly increased during the reporting period.